Objective To investigate the clinical effect of salmeterol fluticasone propionate combined with montelukast in the treatment of moderate and severe bronchial asthma. Methods 112 patients with moderate and severe bronchial asthma in Taizhou hospital from January 2014 to December 2016 were selected and divided into the control and the study group according to the time of visiting hospital, 56 cases in each group. The control group were given salmeterol fluticasone propionate for treatment, the study group were treated with salmeterol fluticasone propionate combined with montelukast .Keep a record of the asthma control test (ACT), forced expiratory volume (FEV1) percentage expected index changes of pre-treatment and 8 weeks after treatment. Results ACT score and FEV1 percentage expected index changes of two groups there was no significant difference before the treatment. After treatment, ACT score and FEV1 percentage expected index changes of the study group was better than the control group(P<0.05). Conclusion Salmeterol fluticasone propionate combined with montelukast in the treatment can significantly improve the clinical efficacy of patients.%目的 探讨沙美特罗替卡松联合孟鲁司特钠治疗中重度支气管哮喘的临床应用效果.方法 选取温州医科大学附属浙江省台州医院2014年1月~2016年12月收治的112例中重度支气管哮喘患者作为研究对象,经单双数字法(入院就诊顺序)随机均分为研究组和对照组,每组各56例.对照组以沙美特罗替卡松治疗,研究组采用沙美特罗替卡松联合孟鲁司特钠片治疗,记录2组中重度支气管哮喘患者治疗前、治疗8 w后哮喘控制测试(ACT)、1秒用力呼气容积(FEV1)占预计值百分比指标变化情况.结果 治疗前2组ACT评分、FEV1/预计值对比差异无统计学意义;治疗后研究组ACT评分、FEV1/预计值指标值均较之前提高.且幅度优于对照组,差异具有统计学意义(P<0.05).结论 沙美特罗替卡松联合孟鲁司特钠治疗中重度支气管哮喘可显著提高患者临床疗效.
展开▼
